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ABSTRACT Synthetic C peptides, corresponding to the
C helix of the HIV type 1 (HIV-1) gp41 envelope protein, are
potent inhibitors of HIV-1 membrane fusion. One such pep-
tide is in clinical trials. The crystal structure of the gp41 core,
in its proposed fusion-active conformation, is a trimer of
helical hairpins in which three C helices pack against a central
coiled coil. Each C helix shows especially prominent contacts
with one of three symmetry-related, hydrophobic cavities on
the surface of the coiled coil. We show that the inhibitory
activity of the C peptide C34 depends on its ability to bind to
this coiled-coil cavity. Moreover, examining a series of C34
peptide variants with modified cavity-binding residues, we
find a linear relationship between the logarithm of the inhib-
itory potency and the stability of the corresponding helical-
hairpin complexes. Our results provide strong evidence that
this coiled-coil cavity is a good drug target and clarify the
mechanism of C peptide inhibition. They also suggest simple,
quantitative assays for the identification and evaluation of
analogous inhibitors of HIV-1 entry.
Recent crystal structures of the envelope protein subunits
gp120 (1) and gp41 (2–4) have raised hopes of structure-based
drug development against HIV type 1 (HIV-1) entry, an
essential step in viral pathogenesis. This step is not targeted by
current combination therapies. gp41 is the transmembrane
subunit that mediates fusion of viral and cellular membranes.
The gp41 ectodomain core is a six-helix bundle composed of
three helical hairpins, each consisting of an N helix paired with
an antiparallel C helix (2–4). The N helices form an interior,
trimeric coiled coil with three conserved, hydrophobic
grooves; a C helix packs into each of these grooves (Fig. 1).
This structure likely corresponds to the core of the fusion-
active state of gp41 (2, 3) and shows similarity to the proposed
fusogenic structures of envelope fusion proteins from influ-
enza (5, 6), Moloney murine leukemia virus (7), and simian
immunodeficiency virus (8, 9).
Synthetic C peptides (peptides corresponding to the C helix),
such as DP178 and C34 (see Fig. 1 legend), potently inhibit
membrane fusion by both laboratory-adapted strains and
primary isolates of HIV-1 (8, 10–12). A Phase I clinical trial
with the C peptide DP178 suggests that it has antiviral activity
in vivo, resulting in reduced viral loads (43). The structural
features of the gp41 core suggest that these peptides act
through a dominant-negative mechanism, in which exogenous
C peptides bind to the central coiled coil of gp41 and lead to
its inactivation (2, 3, 13–15).
Within each coiled-coil interface is a deep cavity, formed by
a cluster of residues in the N helix coiled coil, that has been
proposed to be an attractive target for the development of
antiviral compounds (2). Three residues from the C helix
(Trp-628, Trp-631, and Ile-635) insert into this cavity and make
extensive hydrophobic contacts (Fig. 1). Mutational analysis
indicates that two of the N-helix residues (Leu-568 and Trp-
571) comprising this cavity are critical for membrane fusion
activity (16). Therefore, compounds that bind with high affin-
ity to this cavity and prevent normal N and C helix pairing may
be effective HIV-1 inhibitors. The residues in the cavity are
highly conserved among diverse HIV-1 isolates. Moreover, a
C peptide (T649) containing the cavity-binding region is much
less susceptible to the evolution of resistant virus than DP178,
which lacks this region (17). These observations suggest that
high-affinity ligands targeting the highly conserved coiled-coil
surface, particularly its cavity, will have broad activity against
diverse HIV isolates and are less likely to be bypassed by
drug-escape mutants.
Although this hypothesis is tempting, there is no evidence
that the C34 residues projecting into the cavity are important
for the potency of this inhibitor. In fact, some C peptides that
lack the cavity-binding residues, such as DP178, are highly
effective inhibitors of HIV-1 membrane fusion. We have
performed a systematic structure-function analysis of the role
of cavity contacts for the inhibitory activity of C34. Our results
indicate that cavity-binding residues in C34 are important for
the inhibitory activity of this peptide. Moreover, we show that
there is a striking relationship between the stability of these
cavity contacts and the potency of C34 in inhibiting membrane
fusion.
MATERIALS AND METHODS
Peptide Synthesis and Purification. Mutant peptides were
synthesized by solid-phase fluorenylmethoxycarbonyl peptide
chemistry as described (18) and have an acetylated amino
terminus and an amidated carboxyl terminus. After cleavage
from the resin, peptides were desalted with a Sephadex G-25
column (Pharmacia) and purified by reverse-phase HPLC
(Waters) on a Vydac (Hesperia, CA) C18 preparative column
using a linear water-acetonitrile gradient and 0.1% trif luoro-
acetic acid. Peptide identities were verified by matrix-assisted
laser-desorption ionization mass spectrometry (Voyager Elite,
PerSeptive Biosystems, Cambridge, MA), and their purities
(.98%) were evaluated by analytical HPLC. Peptide concen-
trations were measured by tryptophan and tyrosine absorbance
(at 280 nm) in 6 M guanidine HCl (19). The concentration of
the Trp-631 3 Nal peptide was measured by Nal absorbance
using the extinction coefficient « 5 6,900 at 282 nm (20).
CD Measurements. CD measurements were performed in
PBS (50 mM sodium phosphatey150 mM NaCl, pH 7.0) with
an Aviv Model 62DS spectrometer as described (14). The
apparent melting temperature (Tm) of each complex was
estimated from the maximum of the first derivative of u222 with
respect to temperature.The publication costs of this article were defrayed in part by page charge
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Peptide Inhibition Assays. The potency of C34 peptides in
inhibiting viral infection was determined using recombinant
luciferase-expressing HIV-1 as described (8). To produce
virus, 293T cells were co-transfected with the envelope-
deficient HIV-1 genome NL43LucR-E- (21) and the HXB2
gp160 expression vector pCMVHXB2 gp160 (D.C.C. and
P.S.K., unpublished data) using calcium phosphate. Viral
supernatants were cleared of cellular debris by low-speed
centrifugation and used to infect HOS-CD4yFusin cells (N.
Landau, National Institutes of Health AIDS Reagent Pro-
gram) in the presence of varying concentrations of peptide,
ranging from 0 to 200 nM. Cells were harvested 48 hr
postinfection, and luciferase activity was measured in a Wallac
(Gaithersburg, MD) AutoLumat LB953 luminometer. The
IC50 is the peptide concentration that results in a 50% decrease
in activity relative to control samples lacking peptide. For each
peptide, data from three experiments were fit to a Langmuir
equation [y 5 ky(1 1 ([peptide]yIC50)], where y 5 luciferase
activity and k is a scaling constant] to obtain the IC50 values.
Syncytia formation was assayed by coculturing the HXB2
envelope-expressing cell line Chinese hamster ovary
[HIVe](clone 7d2) (22) with the CD4-expressing cell line
HeLa-CD4-LTR-Beta-gal (M. Emerman, National Institutes
of Health AIDS Reagent Program) in the presence of varying
B
Met629
Arg633Trp631
Ile635
Trp628
A
FP TM
s   s
heptad repeat 1 heptad repeat 2
N36 C34
546 628581 661
SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL
| | | |
INTRA
FIG. 1. HIV-1 gp41 structure and mutant peptides. (A) Schematic of HIV-1 gp41 showing the N36 and C34 peptides, located within two regions
containing 4,3 hydrophobic heptad repeats (white and purple boxes). The residues corresponding to the peptides discussed in this paper are as
follows: C34, 628–661; DP178, 638–673; T649, 628–663. All of these peptides are acetylated at the amino terminus and amidated at the carboxy
terminus. Colored residues in C34 were mutated in this study. Red residues project into the N36 cavity, whereas blue residues do not. FP, fusion
peptide; S-S, disulfide bond; TM, transmembrane region; INTRA, intraviral region. (B) The N36yC34 crystal structure of the HIV-1 gp41
ectodomain core (2). (Left) The trimeric N36 coiled coil is represented by white three helices overlaid with a semitransparent white molecular
surface. Three C34 helices (shown in purple with selected side chains) pack against this coiled coil surface. The bottom of the N36 surface contains
three symmetry-related cavities (one is outlined by the box), each of which accommodates three hydrophobic residues (red) from a C34 helix. In
contrast, the blue residues project outward and do not make contacts with the coiled coil. (Right) A close-up of the cavity region with the C34
residues labeled. Here, the surface of the central coiled coil is represented by an opaque molecular surface. This figure was made with the program
GRASP (42).
15614 Medical Sciences: Chan et al. Proc. Natl. Acad. Sci. USA 95 (1998)
concentrations of peptide, ranging from 0 to 200 nM. Cell
fusion results in expression of nuclear b-galactosidase from the
HeLa-CD4-LTR-Beta-gal indicator cell line. Fifteen hours
after coculture, monolayers were stained with the colorimetric
substrate 5-bromo-4-chloro-3-indolyl-b-D-galactoside, and
syncytia formation was quantitated by counting multinucle-
ated cells containing at least three b-galactosidase-positive
nuclei. For each peptide, data from three experiments were fit
to a Langmuir equation to obtain the IC50 values.
RESULTS
Cavity-Binding Residues of C34 Stabilize Its Interaction
with N36. To determine the role of cavity contacts in inhibitory
activity, we performed structure-based mutagenesis on C34.
The core of the gp41 ectodomain (Fig. 1) was reconstituted
with two synthetic peptides called N36 and C34 (2, 23).
Variants of the C34 peptide with single alanine substitutions
were synthesized, and the helical content and thermal stability
of mutant N36yC34 complexes were quantitated by circular
dichroism. As expected, mutation of C34 residues (Met-629,
Arg-633) that do not contact the N36 coiled coil had little
effect on mean residue ellipticity at 222 nm (u222, a measure of
helical content) or stability of N36yC34 complexes (Table 1).
However, mutation of any of the three residues (Trp-628 3
Ala, Trp-631 3 Ala, or Ile-635 3 Ala) that project into the
cavity of the N36 coiled coil resulted in N36yC34 complexes
with substantially decreased mean residue ellipticity and sta-
bility (Table 1). It should be noted, however, that in the case
of the Trp-628 3 Ala and Trp-631 3 Ala mutations, the
decrease in u222 is likely to overestimate the actual reduction
in helical content. The removal of tryptophan residues from
model helices has been reported to significantly reduce the
absolute value of u222 even when there is little change in helical
content (24). The greatest destabilization was observed with
the mutant Trp-6313Ala, which formed N36yC34 complexes
with an apparent Tm of 37°C, compared with 66°C for wild
type. These results demonstrate that C34 residues making
contacts with the N36 cavity are important for stabilizing the
helical-hairpin structure of the gp41 ectodomain core.
Cavity-Binding Residues of C34 Are Important for Inhibi-
tion of Fusion. To determine the importance of these residues
in the ability of C34 to inhibit membrane fusion, we tested the
activity of these C34 peptides in HIV-1 viral entry and
syncytium assays (Table 1). Wild-type C34 showed IC50 values
of '2.1 nM and '0.55 nM for inhibition of viral entry and
syncytia formation, respectively. For comparison, the reported
IC50 of DP178 is '20 nM for HIV entry (10) and '0.4 nM for
syncytia formation (12). Mutations that had little effect on the
stability of the N36yC34 complex (Met-629 3 Ala and Arg-
633 3 Ala) also had little effect on the inhibitory activity of
C34. However, mutation of the strictly conserved Trp-628 or
Trp-631 to alanine resulted in a substantial decrease in activity:
'5-fold and '30-fold, respectively (Table 1). Mutation of the
less well-conserved Ile-635 resulted in only a '2-fold decrease
in inhibitory activity.
The Potency of C34 Is Directly Related to Its Ability to Bind
the Cavity. To clarify the relationship between the potency of
mutant C34 peptides and the stability of mutant N36yC34
complexes, we took advantage of the greatly destabilizing
effect of the Trp-631 mutation to construct a series of N36y
C34 complexes with a gradation of stabilities. By using the
Trp-631 position as a ‘‘guest site,’’ we systematically substituted
the tryptophan with natural and unnatural amino acids rep-
resenting a broad range of hydrophobic bulk. In order of
increasing hydrophobic bulk, the substitutions were: glycine,
alanine, L-a-aminobutyric acid, valine, leucine, phenylalanine,
the wild-type residue tryptophan, and L-b-(1-naphthyl) ala-
nine. This approach resulted in a set of C34 peptides that form
N36yC34 complexes with Tm values ranging from 35°C to 66°C
(Table 2). In HIV-1 infection and syncytium assays, these
peptides show potencies that correlate with the Tm values of
the corresponding N36yC34 complexes (Fig. 2). The potency
order of these mutants is wt ' Nal . Phe . Leu . Val ' Abu
Table 1. Stability of mutant N36yC34 complexes and the inhibitory potency of C34 mutants
Peptide
[u]222,
103 deg cm2 dmol21
Tm,
°C
IC50, viral entry,
nM
IC50, cell fusion,
nM
Wild-type C34 231.7 66 2.1 6 0.31 0.55 6 0.03
Cavity-binding
Trp-628 3 Ala 227.0 53 10 6 2.0 3.8 6 0.33
Trp-631 3 Ala 224.9 37 61 6 16 15 6 0.82
Ile-635 3 Ala 225.9 55 4.1 6 0.91 0.96 6 0.12
Control residues
Met-629 3 Ala 232.0 66 2.0 6 0.27 0.74 6 0.03
Arg-633 3 Ala 230.7 65 2.6 6 0.89 0.76 6 0.07
Mutant C34 peptides (10 mM) were complexed with the N36 peptide (10 mM) in phosphate-buffered
saline (pH 7.0) for CD measurements. The apparent (Tm) were estimated from the thermal dependence
of the CD signal at 222 nm. Inhibition of viral entry was measured in a cell-culture infection assay using
recombinant luciferase-expressing HIV-1. Inhibition of cell-cell fusion was measured in a syncytium assay.
The means and standard errors were from triplicate trials.
Table 2. Substitution of Trp-631 with a series of hydrophobic amino acids
Peptide
[u]222,
103 deg cm2 dmol21
Tm,
°C
IC50, viral entry,
nM
IC50, cell fusion,
nM
Wild-type C34 231.7 66 1.5 6 0.2 0.55 6 0.03
Trp-631 3 Nal 232.0 62 1.4 6 0.3 0.79 6 0.08
Trp-631 3 Phe 226.3 59 3.6 6 0.8 1.6 6 0.05
Trp-631 3 Leu 226.7 50 5.3 6 1.0 3.2 6 0.1
Trp-631 3 Val 223.9 43 13 6 2.8 4.5 6 0.09
Trp-631 3 Abu 223.2 43 16 6 4.8 6.9 6 0.4
Trp-631 3 Ala 224.9 37 40 6 4.3 15 6 0.8
Trp-631 3 Gly 217.1 35 38 6 6.1 25 6 3.8
Values were determined as in Table 1. The means and standard errors for the inhibition assays were
from triplicate trials.
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. Ala ' Gly, in close agreement with the hydrophobic bulk of
the substitution and the stability of N36yC34 complexes (Table
2). There is a striking linear relationship when the IC50 is
plotted on a logarithmic scale as a function of the Tm (Fig. 2).
Because DG 5 2RTlnK (DG, change in free energy; R, gas
constant; T, absolute temperature; and K, equilibrium con-
stant) and DTm (Tm, wt 2 Tm, mutant) is proportional to DDG
(DGwt 2 DGmutant) (25), the observed relationship strongly
suggests that the potency of the C34 variants is directly related
to their affinity for the N helix coiled coil, as predicted by a
dominant-negative mode of inhibition.
DISCUSSION
Our results provide strong support for the proposal that the
cavity on the gp41 coiled coil is an attractive drug target (2).
Conserved residues projecting into the hydrophobic cavity
clearly play a major role in the ability of C34 to inhibit HIV-1
infection, indicating that this inhibitor works by forming a
high-affinity complex with the N helix coiled coil. Although
the importance of cavity contacts in the potency of C34 is clear,
it remains a challenge to isolate small molecules that bind to
the cavity with sufficient affinity to inhibit HIV-1 infection.
Short peptides consisting of only the cavity-interacting portion
of C34 lack inhibitory activity (D.C.C., D. M. Eckert, C.T.T.,
and P.S.K., unpublished results). However, modification of
C peptides by covalent linkages has been reported to increase
the helicity and potency of shortened C peptides (26). Moving
beyond traditional peptides, mirror-image phage display tech-
niques (27) and combinatorial chemistry (28–30) may be
useful in identifying D peptides, peptidomimetics, and small
molecules that bind with high affinity to the cavity. The close
correlation between N36yC34 stability and C34 inhibitory
potency suggests that the effectiveness of such compounds will
depend critically on the strength of their cavity contacts.
Indeed, our results suggest that candidate compounds can be
tested for the ability to form a stable complex with N36,
thereby providing a basis for rapid, quantitative screens to
identify and evaluate potential inhibitors of HIV-1 entry.
These studies on the mechanism of C peptide action also
support the hypothesis that the trimeric hairpin structure of the
gp41 core (2–4) corresponds to the fusion-active state of gp41.
Our studies show that the inhibitory potency of C34 depends
on its ability to bind to the N helix coiled coil of gp41. Kinetic
studies suggest that C peptides do not act on the native
conformation of gp41 (31) but can act after the onset of rapid
receptor-activated conformational changes (32, 33). Because
the hairpin structure of gp41 is extremely stable, with a melting
temperature in excess of 90°C (14), it is unlikely that nano-
molar concentrations of C34 can disrupt this structure once it
has formed, especially given the high effective concentration of
the N and C helices within an intact gp41 molecule. Rather,
C peptides likely act before the formation of the gp41 hairpin
by binding to a transient pre-hairpin intermediate, in which the
central coiled coil is exposed (13). Binding of C peptides to this
pre-hairpin intermediate inactivates gp41 and prevents its
conversion to the fusion-active hairpin structure. This model is
supported by immunoprecipitation experiments indicating
that the C peptide DP178 binds to receptor-activated gp41
(31). In addition, viruses escaping DP178 inhibition show
mutations in the central coiled-coil region of gp41 (17).
Finally, our findings on HIV-1 gp41 are likely to be relevant
to other membrane fusion events. The gp41 hairpin structure
is similar to fusion proteins from several virus families, in-
cluding retroviruses (7–9), orthomyxoviruses (5), and
paramyxoviruses (34–37). Moreover, these similarities extend
to v-SNARE and t-SNARE protein complexes involved in
vesicle fusion (38–41), suggesting that formation of hairpin
helices may be involved in a wide range of membrane fusion
reactions.
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